Veeam Transforms Kubernetes Data Resilience with Kasten v8, Veeam Vault, and Strategic Red Hat Integration
SEATTLE--(BUSINESS WIRE)-- Veeam ® Software, the #1 global leader by market share in Data Resilience, today announces the launch of Veeam Kasten for Kubernetes v8, designed to bring data resilience to both traditional virtual machines (VMs) and cloud-native environments, delivering unparalleled security and operational efficiency. Veeam Kasten for Kubernetes v8 introduces new innovations in Kubernetes data resilience, providing enterprise-ready modern virtualization, enhanced security, effortless operations at scale, and ultimate customer freedom of choice. This latest release reinforces Veeam's commitment to enabling enterprises to seamlessly manage their data in a unified infrastructure – securely and effortlessly.
'Veeam Kasten for Kubernetes v8 marks a significant leap forward in our mission to provide enterprises with unparalleled data resilience for Kubernetes environments,' said Gaurav Rishi, Vice President of Product Management at Veeam. 'This latest version enables organizations to seamlessly manage traditional VMs and modern applications on a single platform while ensuring data is secure and accessible. New integration with Veeam Vault provides a fully managed offsite backup solution that eliminates unexpected costs, benefiting existing Veeam customers wanting to expand their data protection to include Kubernetes. By consolidating all their data under Veeam's trusted management, customers can implement a comprehensive solution for their Kubernetes application workloads, maximizing operational efficiency and enhance data resilience in today's complex IT landscape.'
New key features and benefits of Veeam Kasten for Kubernetes v8 include:
Enterprise-Ready Modern Virtualization: Kasten v8 unifies data resilience for VMs on Kubernetes alongside containerized applications, streamlining operations and boosting efficiency. The new File Level Recovery (FLR) for KubeVirt VMs allows granular restores that accelerate recovery times and eliminate manual processes, enabling organizations to recover individual files from backups without the need to restore entire VM clones, essential for enterprises adopting solutions including Red Hat OpenShift Virtualization.
Additionally, the new virtual machine dashboard offers a workload-centric view across cluster namespaces to simplify the process of identifying each VM's Kubernetes-dependent resources and makes configuring backup consistency easy.
Freedom of Choice: Enhanced flexibility with multi-CPU architecture support enables organizations to optimize costs using options like ARM and IBM Power. Robust integration with Veeam Vault offers secure, fully managed offsite backups that eliminate unexpected costs, making it ideal for organizations expanding their data protection to include Kubernetes while keeping all data under Veeam's trusted management. Additionally, Veeam broadens support for NetApp Trident storage provisioner with backup capabilities for ONTAP NAS 'Economy' volumes, empowering customers to seamlessly back up across various storage solutions and select the best-fit options for their unique environments.
Security Everywhere: With features like secure, self-service cross-cluster migrations and restricted privileges for Kasten Pods, users can confidently manage their Kubernetes environments while minimizing security risks. Increased security measures, such as restricted privileges for Kasten Pods minimize risks and enhance compliance by adopting a least-privilege approach. ISO 27001 certification demonstrates Veeam's commitment to industry leading security standards, elevating customers' security profiles. Additionally, simplified encryption passkey rotation reduces vulnerabilities, empowering enterprises to maintain robust security while optimizing operational efficiency.
Effortless Operations at Scale: New, refreshed user interface simplifies onboarding, policy creation, and ongoing operations. Enhancements include a streamlined Policy Management system and a Restore Point Catalog, allowing users to easily manage backups and perform restore operations from a high-level view. The Per Policy Protection Status feature allows users to quickly identify policies for specific namespaces, enhancing visibility and facilitating efficient remediation. These enhancements improve the user experience for both new and experienced administrators, making it easier to manage Kubernetes environments at scale.
Kasten for Modern Virtualization
Red Hat OpenShift Virtualization Engine provides a dedicated solution for organizations aiming to replace legacy virtualization capabilities using Red Hat OpenShift platform, the industry's leading hybrid cloud application platform powered by Kubernetes. In support of this VM-first approach, Veeam has released Kasten for Modern Virtualization – a tailored pricing option designed to align seamlessly with Red Hat OpenShift Virtualization Engine. This new offering, developed through Veeam and Red Hat's strong go-to-market collaboration, provides a security-enhanced and cost-effective foundation for modernizing virtualization. It empowers organizations to enhance operational efficiency while paving the way for a cloud-native future.
"Red Hat OpenShift Virtualization Engine provides customers with a dedicated virtualization edition to migrate, manage and scale virtual machines. As enterprises advance their hybrid cloud strategy by rapidly re-hosting virtualized apps to platforms designed for modern virtualization, data resilience remains a strategic imperative,' said Mike Barrett, vice president and general manager, Hybrid Platforms, Red Hat. 'With the latest release of Kasten, Veeam continues to deliver innovation aligned with these evolving needs. Veeam's Kubernetes-native architecture and optimization on Red Hat OpenShift provides our customers with a more scalable, cost-effective solution to secure virtualized workloads today—while laying a strong foundation for container adoption over time.'
Veeam Kasten reflects Veeam's ongoing dedication to empowering enterprises with the tools they need to manage and protect their data effectively in a rapidly evolving landscape. Veeam Kasten for Kubernetes v8 and Kasten for Modern Virtualization are now available. For more information, visit https://www.veeam.com.
About Veeam Software
Veeam®, the #1 global market leader in data resilience, believes every business should be able to bounce forward after a disruption with the confidence and control of all their data whenever and wherever they need it. Veeam calls this radical resilience, and we're obsessed with creating innovative ways to help our customers achieve it.
Veeam solutions are purpose-built for powering data resilience by providing data backup, data recovery, data portability, data security, and data intelligence. With Veeam, IT and security leaders rest easy knowing that their apps and data are protected and always available across their cloud, virtual, physical, SaaS, and Kubernetes environments.
Headquartered in Seattle with offices in more than 30 countries, Veeam protects over 550,000 customers worldwide, including 67% of the Global 2000, that trust Veeam to keep their businesses running. Radical resilience starts with Veeam. Learn more at www.veeam.com or follow Veeam on LinkedIn @veeam-software and X @veeam.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer
At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone SHANGHAI & CAMBRIDGE, Mass., June 30, 2025--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall survival (OS) at a pre-specified interim analysis. Bemarituzumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in OS as compared to placebo plus chemotherapy in people living with unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer with FGFR2b overexpression and who are non-HER2 positive. FGFR2b overexpression was defined as 2+/3+ staining in ≥10% of tumor cells by centrally performed immunohistochemistry (IHC) testing. Gastric cancer is the fifth leading cause of cancer-related death worldwide, with nearly one million new cases and over 650,000 deaths globally each year 1, highlighting a critical unmet medical need. In China, there are over 350,000 new cases each year. The disease is associated with a poor prognosis, particularly in advanced stages where the five-year survival rate is less than 10%. There are currently no approved therapies specifically targeting FGFR2b overexpression in gastric cancer in China. "Bemarituzumab is the first FGFR2b inhibitor to demonstrate a statistically and clinically significant overall survival benefit in a randomized Phase 3 trial for the first-line treatment of FGFR2b-positive gastric cancer," said Dr. Rafael Amado, M.D., President, Head of Global Research and Development at Zai Lab. "The success of the global Phase 3 FORTITUDE-101 study highlights the potential of bemarituzumab to redefine the standard of care for a patient population that has faced poor outcomes with existing therapies. We are proud to have contributed meaningfully to this pivotal trial, including a substantial number of patients enrolled in China. Based on these results, and the regulatory Breakthrough Designation, we plan to move rapidly toward regulatory submission in China to bring this transformative therapy to patients as quickly as possible." The most common treatment-emergent adverse events (>25%) in patients treated with bemarituzumab plus chemotherapy were reduced visual acuity, punctate keratitis, anaemia, neutropenia, nausea, corneal epithelium defect and dry eye. While ocular events were consistent with the Phase 2 experience and observed in both arms, they occurred with greater frequency and severity in the Phase 3 bemarituzumab arm. Detailed results from the trial will be shared at a future medical meeting. Zai Lab holds the development and commercialization rights for bemarituzumab for mainland China, Hong Kong, Macau, and Taiwan. Bemarituzumab has been granted Breakthrough Therapy designation by the China Center for Drug Evaluation of the National Medical Products Administration for the treatment of FGFR2b-positive gastric and gastroesophageal junction adenocarcinoma. A Phase 3 study of bemarituzumab plus chemotherapy and nivolumab is also ongoing in patients with first-line gastric cancer, with data readout anticipated in H2 2025. About FGFR2b The FGFR2b protein (also known as fibroblast growth factor receptor 2b) is an emerging biomarker which, when overexpressed, promotes aberrant signaling leading to tumor cell proliferation.2 The FGFR2b protein is overexpressed by G/GEJ tumor cells in approximately 38% of patients with advanced G/GEJ cancer. FGFR2b protein overexpression is defined as 2+/3+ staining intensity on tumor cell membrane, as detected by immunohistochemistry (IHC) testing. In approximately 16% of patients with advanced G/GEJ cancer, FGFR2b protein overexpression is observed on ≥10% of tumor cells by IHC.3 About FORTITUDE-101 FORTITUDE-101 is a randomized, multi-center, double-blind, placebo-controlled Phase 3 study of bemarituzumab plus mFOLFOX6 versus placebo plus mFOLFOX6 as first-line therapy in advanced G/GEJ cancer with FGFR2b overexpression. The FORTITUDE-101 trial spanned 300 sites across 37 countries, with 547 patients enrolled. The primary outcome measure of the trial is overall survival in patients with FGFR2b ≥10% 2+/3+ tumor cell staining. Key secondary outcome measures include progression-free survival and overall response rate. Candidates were excluded from the trial if they were known to be human epidermal growth factor receptor 2 (HER2) positive. FORTITUDE-101 included more comprehensive ocular-related monitoring than previous studies of bemarituzumab. About Gastric Cancer in China Gastric cancer is the fifth most common cancer worldwide, while China bears one of the highest gastric cancer burdens in the world with an estimated 358,700 new cases and 260,400 deaths annually.4 In China, approximately 80% of gastric cancer patients are diagnosed at an advanced or metastatic stage5. For those diagnosed with Stage IV gastric cancer, the overall 5-year survival rate is less than 10%6. Patients with advanced gastric and GEJ cancer that overexpress the FGFR2b protein may be associated with poor prognosis7-10. About Zai Lab Zai Lab is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health worldwide. For additional information about Zai Lab, please visit or follow us at Zai Lab Forward Looking Statements This press release contains forward-looking statements relating to our future expectations, plans, and prospects, including, without limitation, statements regarding the prospects and plans for developing and commercializing bemarituzumab, the potential benefits of bemarituzumab, and the potential treatment of gastric and gastroesophageal junction cancer. All statements, other than statements of historical fact, included in this press release are forward-looking statements, and can be identified by words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "possible," "potential," "will," "would," and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact or guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. We may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in our forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products, (2) our ability to obtain funding for our operations and business initiatives, (3) the results of our clinical and pre-clinical development of our product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates, (5) risks related to doing business in China, and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Our SEC filings can be found on our website at and the SEC's website at REFERENCES Bray F, et al. CA Cancer J Clin. 2024;74(3);229-263 Wainberg ZA, et al. Lancet Oncol. 2022;23(11):1430-40 Rha SY, et al. JCO Precis Oncol. 2025; 9 (e2400710). DOI:10.1200/PO-24-00710 Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. Health Commission of The People's Republic Of China N. National guidelines for diagnosis and treatment of gastric cancer 2022 in China (English version). Chin J Cancer Res. 2022;34(3):207-237. Li HQ, Zhang H, Zhang HJ, Wang YX, Wang XB, Hou HF. Survival of gastric cancer in China from 2000 to 2022: A nationwide systematic review of hospital-based studies. J Glob Health 2022;12:11014. Catenacci D, et al. Presented at American Society of Clinical Oncology; June 4-8, 2021; Online Virtual Scientific Program. Abstract 4010. Ahn S, et al. Mod Pathol. 2016;29:1095-1103. Ishiwata T. Front Biosci (Landmark Ed). 2018;23:626-639. Wainberg ZA, et al. Lancet Oncol. 2022;23:1430-1440. View source version on Contacts For more information, please contact: Investor Relations: Christine Chiou / Lina Zhang+1 (917) 886-6929 / +86 136 8257 / Media: Shaun Maccoun / Xiaoyu Chen+1 (857) 270-8854 / +86 185 0015 / Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
14 minutes ago
- Business Wire
Carlisle Companies Completes Purchase of Bonded Logic
SCOTTSDALE, Ariz.--(BUSINESS WIRE)-- Carlisle Companies Incorporated (NYSE:CSL) today announced it has completed the previously announced purchase of select assets of Bonded Logic, Inc. and Phoenix Fibers, LLC (collectively as 'Bonded Logic'). Consistent with Carlisle's Vision 2030 strategy and continued emphasis on synergistic M&A, the acquisition of Bonded Logic supports the growth of high-performance Henry ® UltraTouch ® recycled denim insulation, a unique, eco-friendly insulation solution that is easier to install than conventional insulation solutions and diverts millions of pounds of waste from landfills every year. About Carlisle Companies Incorporated Carlisle Companies Incorporated is a leading supplier of innovative building envelope products and solutions for more energy efficient buildings. Through its building products businesses – Carlisle Construction Materials ('CCM') and Carlisle Weatherproofing Technologies ('CWT') – and family of leading brands, Carlisle delivers innovative, labor reducing and environmentally responsible products and solutions to customers through the Carlisle Experience. Carlisle is committed to generating superior shareholder returns and maintaining a balanced capital deployment approach, including investments in our businesses, strategic acquisitions, share repurchases and continued dividend increases. Leveraging its culture of continuous improvement as embodied in the Carlisle Operating System ('COS'), Carlisle has committed to achieving net-zero greenhouse gas emissions by 2050.
Business Wire
19 minutes ago
- Business Wire
Boxlight Celebrates Ruby Jubilee at ISTELive 25 and ASCD Annual 25
DULUTH, Ga.--(BUSINESS WIRE)-- Boxlight Corporation (Nasdaq: BOXL) —recognized as one of the top ed-tech companies in the world for innovative solutions that enhance communication and collaboration in educational institutions and businesses—will mark its 40th anniversary at ISTELive 25 and ASCD Annual 25, June 29–July 2 in San Antonio, Texas. Attendees who visit Booth #2918 will experience the company's latest innovations and see firsthand how Boxlight continues to evolve, inspire and deliver on its mission to improve learning and campus communication and safety with integrated technology. Celebrating a brilliant legacy and a bright tomorrow, Boxlight's Ruby Jubilee reflects four decades of innovation in the edtech space. From its early roots in display technology to its growing ecosystem of integrated classroom, audio and safety solutions, Boxlight remains dedicated to helping schools engage learners, support teachers and strengthen schoolwide communication. 'For 40 years, Boxlight has been listening to educators, adapting to change and building technology that truly supports effective instruction, streamlined operations and safer learning environments,' said Jens Holstebro, Executive Vice President and General Manager at Boxlight. 'We're proud of how far we've come and even more excited about what's ahead. ISTELive 25 is a chance to honor that legacy and showcase solutions that are helping schools across the country stay secure, connected and future-ready.' Highlights at Booth #2918 Attendees looking to improve campus security will see how Conductor and CleverLive now integrate with the safety platforms CrisisGo, Raptor, CENTEGIX, RedBag and Kokomo24/7 through the ATTENTION! ecosystem. These integrations enable schools to quickly and effectively initiate alerts and share critical information across displays, signage and audio systems, improving coordination and response times. They will also demo the latest edtech solutions designed to enhance collaboration, streamline campus operations and help schools and districts create engaging, modern learning environments: Clevertouch Pro Series: A powerful, enterprise-grade display that features built-in Google EDLA certification and gives educators access to Google Play apps, automatic updates and a secure Android 14 experience—ideal for districts leveraging Google tools. IMPACT Max 2: Boxlight's most adaptable classroom display to date combines flexible interface options, rapid touch response and intuitive collaboration tools that support diverse teaching styles and dynamic student interaction. CL Totem: A sleek, freestanding digital signage solution that delivers high-impact messaging without the need for wall mounting, subscriptions or complex infrastructure—perfect for school entrances, hallways and shared spaces. Campus-Wide Audio Solutions: Boxlight's audio lineup, including FrontRow Juno, ezRoom and Lyrik, ensures clear, consistent sound across classrooms and entire campuses, supporting both instructional clarity and emergency communication. Visitors to the Boxlight booth will also have the opportunity to connect with Boxlight team members, who will be on hand to provide product demos, answer questions and discuss how Boxlight can support district goals. Free Guest Passes Available Those who wish to explore the ISTELive 25 and ASCD Annual 25 Expo Hall can request a free guest pass from Boxlight. To learn more or to download a pass, visit Boxlight Corporation (Nasdaq: BOXL) is a leading provider of interactive technology solutions under its award-winning brands Clevertouch®, FrontRow™ and Mimio®. The Company aims to improve engagement and communication in diverse business and education environments. Boxlight develops, sells and services its integrated solution suite including interactive displays, collaboration software, audio solutions, supporting accessories and professional services. For more information about Boxlight and the Boxlight story, visit and and
